Department of Pediatrics, Division of Pediatric Allergy and Immunology, Duke University Medical Center, Durham, NC 27710, USA.
J Allergy Clin Immunol. 2011 Jan;127(1):81-8. doi: 10.1016/j.jaci.2010.09.014. Epub 2010 Nov 18.
Allergic reactions to tree nuts are often severe and are outgrown in less than 10% of diagnosed patients.
To determine whether treatment of underlying tree nut sensitization will prevent allergic reactions to cross-reacting tree nuts and to determine the effects of single-tree nut immunotherapy on true multi-tree nut sensitization.
Cross-reactivity model: Cashew-sensitized mice underwent immunotherapy with cashew and were subsequently challenged with cashew and pistachio. Multisensitization model: Cashew plus walnut-sensitized mice were treated with cashew alone, walnut alone, or both cashew and walnut and then underwent challenges to cashew and walnut. Challenges were assessed on the basis of symptoms, changes in body temperature, and mouse mast cell protease-1 release.
In the cross-reactivity model, cashew immunotherapy completely prevented allergic reactions on challenges with cashew or the cross-reactive pistachio. In the multisensitization model, mice with cashew plus walnut allergy were significantly protected from anaphylactic reactions on cashew challenge in both the cashew-alone and walnut-alone immunotherapy groups. Results from the walnut challenge demonstrated significantly decreased allergic responses in the walnut immunotherapy group, whereas mice in the cashew immunotherapy group experienced significantly lower symptoms. In the cross-reactivity model, immunotherapy effectively decreased IL-4 and IL-5 production and increased IL-12 relative to placebo while also inducing a 5-fold increase in specific IgG(1).
Single-tree nut immunotherapy can effectively decrease allergic responses in both the cross-reactivity and multisensitization mouse models. Further studies are needed to determine which single-tree nut immunotherapies will be most effective for specific multi-tree nut allergy profiles.
树坚果过敏反应通常较为严重,在确诊患者中不到 10%的患者会随着时间推移而过敏反应减轻。
确定针对树坚果致敏原的治疗是否能预防交叉反应性树坚果的过敏反应,以及确定单一树坚果免疫疗法对真正的多树坚果致敏的影响。
交叉反应模型:腰果致敏的小鼠接受腰果免疫治疗,然后用腰果和开心果进行挑战。多致敏模型:同时致敏于腰果和胡桃的小鼠单独用腰果、胡桃或两者进行治疗,然后用腰果和胡桃进行挑战。根据症状、体温变化和鼠肥大细胞蛋白酶-1释放来评估挑战。
在交叉反应模型中,腰果免疫治疗完全预防了用腰果或交叉反应性开心果进行挑战时的过敏反应。在多致敏模型中,同时对腰果和胡桃过敏的小鼠在单独用腰果和单独用胡桃免疫治疗组中,在对腰果的挑战中均显著受到保护,避免了过敏反应。在胡桃的挑战中,胡桃免疫治疗组的过敏反应明显减少,而在腰果免疫治疗组中,症状明显减轻。在交叉反应模型中,与安慰剂相比,免疫治疗可有效减少 IL-4 和 IL-5 的产生,增加 IL-12,同时诱导特异性 IgG(1)增加 5 倍。
单一树坚果免疫疗法可有效减少交叉反应和多致敏模型中的过敏反应。需要进一步的研究来确定哪种单一树坚果免疫疗法对特定的多树坚果过敏症谱最有效。